Date
Attendees
Committee Member | Present | Absent |
---|---|---|
X | ||
Amy Leblanc | X | |
X | ||
X | ||
X | ||
Debbie Knapp | ||
Toby Hecht | X | |
Ralph Parchment | X |
Goals
- Discuss updates to ICDC and define emerging strategies and priorities
SharePoint Site
https://nih.sharepoint.com/sites/NCI-CBIIT-FNL-ICDC-ICDCLeadershipGroups
Outstanding Action Items
- Debbie to work with Ralph to write invitation for Jaime Modiano
- Gina to speak with Debbie to arrange a meeting with Gerry to discuss data submission (Toby, Debbie, Phil)
- Revisit new steering committee members in September (loop Connie into this discussion)
Agenda
Item | Who | Talking Points |
---|---|---|
Discussion with FidoCure | Dr. Gerald Post, Chief Medical Officer at FidoCure Ben Toussant, Vice President of Operations at FidoCure |
|
New ICDC Subcommittee: Cross-Species Mapping Committee (CSMC) Purpose: Facilitation of human-canine comparative data analysis from the ICDC and other nodes in the CRDC using interoperability components such as Cancer Data Aggregator and aligning with data standards | All |
|
New ICDC Subcommittee: Longitudinal Data Acquisition and Use Committee (LDAUC) Purpose: Formulate scientific questions and use cases that can be used to interrogate longitudinal datasets that would justify the ingestion of such data into the ICDC.. | All |
|
DGAB Updates | Recently Released ICDC Studies in Active Submission
| |
New ICDC Bioinformatics Tutorial Website |
| |
ICDC Biospecimen Data |
| |
Upcoming Steering Committee Meeting | Ralph Parchment |
|
Minutes (Not Verbatim)
Discussion with FidoCure
_______________________
Specific AI Question:
-Tumor, mutation, drug targets, inform outcomes correlation between
-Build dataset and R & D
-Improve outcomes for patients with diagnostics and therapy
-FidoCure is actually called OneHealth, dogs can be an unparalleled comparative model. We have the largest canine cancer dataset in the world, approaching 2 billion data points. Working on both sides of the leash.
Previous ICDC Use Cases from Steering Committee
1. Genomic correlates across platforms (DNA, RNA, protein).
2. Correlating multi-omics data with clinical annotation and phenotypes, particularly outcomes.
3. Comparative analyses of canine and human. Examples include:
1. Search for conserved mutations between canine and human tumors
2. Disease diagnosis (e.g. cancer type) and classification mapping between canines and humans
5. Gene expression changes and mutational profiles associated with therapeutic response and outcome
6. How do sporadic tumors in non-human mammals compare to sporadic human tumors?
7. Correlations and model building from radiomic and pathomic features extracted from medical and histopathologic images with outcomes and genomics, as is currently being widely done with human images
8. Develop biomarkers of response and resistance in humans by analyzing the responses and genomic signatures in dogs.
Action items
- Toby to invite Greg from CCDI to the next Executive Team Meeting in January
- Toby to look across the NCI directory to find person that has a combination of canine and pediatric oncology background